Health
Africa needs vaccines. What would it take to make them here?
The authors of this article show that, by their estimates, the public market for vaccines in Africa could rise from $1.3 billion today to between $2.3 billion and $5.4 billion by 2030 (depending on the scenario). While Africa’s population is growing faster than that of most other regions, significant immunization coverage gaps remain, and new products (such as vaccines for Lassa fever or malaria) could be introduced and used widely on the continent. Leaders are increasingly aware of the importance of health security, both for its own sake and as a critical tool for securing the continent’s development, and are increasingly heeding calls for investments into vaccine manufacturing to prevent African countries from being last in line for vital supplies.
Podcast about vaccines and IP protection
Munk Debates wants to help the world rediscover the art of civil and substantive public debate by convening the brightest thinkers of our time to weigh in on the big issues of the day. Their debate on vaccines provides two interesting perspectives on the vaccine rollout and IP protection.
GSIV finalists transforming health in developing markets
The UNDP, EPFL, Orange, and SAP have selected Livox, Bempu Health, Vula Mobile, and Mamotest as the health finalists for the Growth Stage Impact Ventures (GSIV) initiative. From Brazil, India, South Africa, and Argentina, respectively, these midcap companies went through GSIV’s rigorous selection process and emerged as the most impactful and investment-ready ventures, providing products and services to facilitate access to quality health care at the bottom of the pyramid.
Healthcare Innovation Main Driver of European Patent Applications in 2020
The latest statistics published by the European Patent Office (EPO) show that innovation in healthcare was the main driver of patenting activity in 2020. Medical technology was the field with the most inventions by volume, while pharmaceuticals and biotechnology were the fastest-growing areas. Indeed, in 2020, medical technology retook the top spot for most inventions (from the field of digital communication), while pharmaceuticals and biotech showed 10.2% and 6.3% increases in patent filing, respectively.
Covid Vaccines: Intellectual Property and Access, a Melting Pot of Viewpoints
Innovation Council member SARIMA has published an article by Dr Andrew Bailey, in which he explains the various views on the issue of access to IP in light of the COVID-19 pandemic. He sees a need for governments to build capacity in the manufacture of vaccines, in order to both meet local demand and assist with pandemic response.
During the pandemic, there was incredible collaboration across institutional, corporate, and national boundaries to address the urgent health crisis. Bailey hopes that this experience will shape global thinking about collaboration, and about how to ensure equitable access to healthcare whilst taking care to properly respect the infrastructural investments, trade secrets, and know-how of manufacturers.
Bio-Pharmaceutical Manufacturing and R&D: The Impact of Policy Coherence in Trade Policy
This Innovation Council working paper illustrates the importance of policy coherence in the realm of biopharmaceutical manufacturing and R&D. Specifically, it shows that investing in diversified, geographically dispersed sources of R&D and production can increase manufacturing capacity and strengthen health security by complementing existing pharmaceutical production chains, thus making them less vulnerable to future supply chain shocks. It shows that counterproductive trade measures, such as tariffs on the development and production of vaccines and other health technologies, can slow development, and that—especially in light of the experience of Covid-19—distributed manufacturing and R&D capabilities are particularly useful in the area of biopharmaceuticals.
The pandemic has inspired and challenged medical innovation
The need for new and more effective methods of prevention and treatment is constant, and the spread of COVID-19 has emphasized that demand. During the Farley Center for Entrepreneurship and Innovation’s “Healthcare Innovation during the COVID-19 Pandemic” discussion on February 12, experts from academia and industry examined the latest advances in the field and how the very process of medical innovation is being reinvented amid the greatest global health crisis in at least a century. One conclusion they found: Reinventing innovation can mean re-applying ideas used previously.
Considering All Sides of Medicines Patents
For many years, policy experts and others have engaged in wide-ranging debates about patents on pharmaceuticals, particularly in developing countries. On the one hand, it has been argued that IP protection provides crucial incentives to the pharmaceutical industry to undertake more research on tropical diseases. On the other hand, the patenting of pharmaceuticals has been criticised as causing challenges regarding access to medicines. The brief examines in detail the rationale for patenting medicines. The examination includes an investigation into the role of the patent system in relation to the pharmaceutical industry, the moral limits of patents, how the exclusion of a patent can create social costs, the rationale for the patenting of medicines and the incentive theory and how this can be balanced with access to medicines.
Patenting and Covid-19 Vaccines
Patents have had an important role in organising the collaborations that led to the development and commercialization of COVID-19 vaccines. Patenting is a crucial tool in research-based industries like pharmaceuticals and biologics and can be a means to encourage collaboration. Terms can be negotiated to have different types of expertise combined in one project. The virus will likely garner another sort of PIP-type or any other similar program which will encourage contractual licensing of innovative IP in exchange for access to specialized expertise or important biological data. Monopolisation should clearly be avoided, and patent pooling must be the way forward to obtain sufficient vaccines for Covid-19 as early as possible.
Healthcare Needs More Diverse Experts To Guide Innovation
According to Silicon Valley Bank, total healthtech investment in 2020 was $15.3 billion, compared to just $10.6 billion in 2019. While healthcare deals were up across the board, a trend towards telehealth, virtual clinical trials, and other remote practices helped bring digital health to the forefront. However, many great ideas failed simply because they lacked access to knowledgeable insiders. And those experts that did exist tended to be monolithic or act as gatekeepers rather than sources of valuable guidance. Shelli Pavone founded Inlightened to help bridge that gap and break the hold of those gatekeepers. By creating a vast network of diverse healthcare experts for innovators to tap for guidance, she hopes to nudge more good ideas towards solving healthcare’s most compelling problems.
South Africa: Covid Vaccine Manufacturing
To battle COVID-19, the world will need vaccines. Expanding global manufacturing capacity is part of ensuring there are enough to go around. Biovac, based in South Africa, is committed to the long fight against the pandemic. The CEO, Dr Morena Makhoana, estimates that Biovac will be able to produce as many as 30 million doses of a Covid-19 vaccine. Biovac is part-owned by the South African Government. The company is still engaged in talks with global pharmaceutical companies regarding manufacturing and producing Covid-19 vaccines at its facilities in South Africa. The emergence of the second, more lethal variant has added some complexity – and urgency.
How the pandemic catalyzed innovation in health IT, per 8 hospital execs
The COVID-19 pandemic accelerated innovation at hospitals across the USA by forcing them to adopt new, digitally focused ways of delivering care, paving the way for further tech-enabled improvements after the pandemic subsides. In this interview, eight hospital and health system innovation leaders weigh in on how healthcare innovation trends have grown amid the pandemic.
The interviewees acknowledge that the pandemic has taken away everyone’s excuses as to why telehealth cannot work and instead made them focus on how and why it must work. Before the pandemic, most traditional brick-and-mortar providers in our industry saw telehealth as a threat and were thus quite biased to focus on its shortcomings. Not surprisingly, they were quick to point out why telehealth was not ideal – or even ‘dangerous’ – for ‘most’ encounters. Payers sang the same tune, as they have always been wary of the potential for unchecked overutilization of telehealth.